Vivani Medical (Nasdaq: VANI) fully doses participants in SLIM-1 obesity implant trial
Rhea-AI Filing Summary
Vivani Medical, Inc. reports full enrollment and successful initial dosing of all 20 participants in SLIM-1, a Phase 1 trial of NPM-139, a miniature, subdermal semaglutide implant for chronic weight management. The randomized, controlled trial evaluates safety, tolerability and pharmacokinetics versus low-dose Wegovy injection in GLP-1 naïve participants in Australia.
NPM-139 uses Vivani’s NanoPortal implant platform, which is being designed to deliver semaglutide continuously for six to twelve months and to allow rapid reversal of drug exposure when needed. SLIM-1 runs over four weeks, with top-line data from the 20-participant study expected in November 2026 and anticipated to inform a planned Phase 2 dose-ranging trial in 2027. Vivani also highlights preclinical studies showing sustainable 20% weight reduction in animal models and a July 2026 agreement with Novo Nordisk to evaluate NPM-139 and the NanoPortal technology.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
SLIM-1 participants: 20 participants
First cohort dosing: 10 participants
Second cohort dosing: 10 participants
+5 more
8 metrics
SLIM-1 participants
20 participants
Phase 1 trial size for NPM-139 in Australia
First cohort dosing
10 participants
First 10 SLIM-1 participants dosed on July 29, 2026
Second cohort dosing
10 participants
Remaining 10 SLIM-1 participants dosed one week after July 29, 2026
Treatment duration
four-week duration
Period over which NPM-139 and Wegovy are administered in SLIM-1
Intended drug delivery period
six- to twelve-months
Target continuous semaglutide delivery from the NPM-139 implant
Wegovy starting dose
0.25mg/week
Comparator semaglutide injection dose given to 10 participants
Preclinical weight reduction
20%
Sustainable weight reduction observed in NPM-139 animal studies
Medication non-adherence
approximately 50%
Share of patients not taking medication as prescribed across conditions
Key Terms
Phase 1 trial, pharmacokinetics, GLP-1 naïve, subdermal semaglutide implant, +1 more
5 terms
Phase 1 trial medical
"SLIM-1™ trial is a Phase 1, randomized, controlled clinical trial"
Phase 1 trial is the first stage of testing a new drug or treatment in humans, focused mainly on safety, tolerability and finding the right dose, usually in a small group of volunteers or patients. For investors it matters because clear safety and dosing results reduce development risk, unlock later, larger trials, and can meaningfully change a biotech’s value and timeline — like a prototype’s maiden test flight that shows whether further investment makes sense.
pharmacokinetics medical
"designed to characterize the safety, tolerability, and pharmacokinetics of NPM-139"
Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.
GLP-1 naïve medical
"The trial of 20 GLP-1 naïve participants in Australia includes low-doses"
subdermal semaglutide implant medical
"NPM-139, a miniature, subdermal semaglutide implant being designed"
medication non-adherence medical
"Medication non-adherence occurs when patients do not take their medication"
Medication non-adherence is when patients do not take prescribed drugs as directed — for example missing doses, taking the wrong amount, stopping early, or using the medication at the wrong times. For investors, it matters because poor adherence can make a drug look less effective in trials, reduce real-world sales and repeat prescriptions, increase healthcare costs, and create unpredictable revenue and regulatory risk—much like customers buying a product but not using it as intended.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Vivani Medical (VANI) announce regarding the SLIM-1 trial?
Vivani Medical announced full enrollment and successful initial dosing of all 20 participants in its SLIM-1 Phase 1 trial of NPM-139, a semaglutide implant for chronic weight management. The study evaluates safety, tolerability, pharmacokinetics and weight changes over a four-week period.
How is the SLIM-1 Phase 1 trial for Vivani Medical (VANI) designed?
SLIM-1 is an open-label, active-controlled Phase 1 trial in 20 GLP-1 naïve participants in Australia. Ten receive low-dose NPM-139 implant and ten receive the starting Wegovy dose (0.25mg/week) over four weeks, assessing safety, tolerability, pharmacokinetics and weight change.
What is NPM-139 in Vivani Medical (VANI)’s pipeline?
NPM-139 is a miniature, subdermal semaglutide implant designed to deliver drug continuously for six to twelve months using Vivani’s NanoPortal platform. It targets chronic weight management and metabolic diseases by improving convenience, adherence and tolerability compared with daily or weekly injections.
When are SLIM-1 top-line data expected for Vivani Medical (VANI)?
Top-line results from the 20-participant SLIM-1 trial are expected in November 2026. Vivani indicates that these data are anticipated to support the initiation of a Phase 2 dose-ranging trial in 2027, further advancing development of the NPM-139 semaglutide implant program.
What is Vivani Medical (VANI)’s relationship with Novo Nordisk?
Vivani reports a July 2026 agreement with Novo Nordisk to evaluate NPM-139 and its NanoPortal implant technology. The collaboration focuses on assessing Vivani’s long-acting GLP-1 implant platform, complementing ongoing clinical development of NPM-139 for chronic weight management.
What preclinical results support Vivani Medical (VANI)’s NPM-139 program?
Preclinical studies of NPM-139 demonstrated sustainable 20% weight reduction in animal models. These results, together with SLIM-1 enrollment and dosing progress, support continued evaluation of Vivani’s long-acting semaglutide implant approach for obesity and type 2 diabetes.